Dr. Gloria Wang

TIOC Therapeutics is a clinical-stage biotechnology company dedicated to developing TCR-TCEs as well as TCR-T products. These products target intracellularly expressed antigens, enabling previously undruggable targets to become viable therapeutic options. Such therapeutics address unmet clinical needs in oncology (particularly malignant solid tumors), infectious diseases, autoimmune disorders, and related areas. As the leader of translational medicine, medical development, pharmacovigilance, and clinical operations within the company, key responsibilities include: • Collaborating closely with basic scientists to translate novel research findings into clinical hypotheses • Defining the Target Product Profile (TPP) in collaboration with company leadership and board members, aligning cross-functional teams (e.g., R&D, clinical, and commercial). Designing and finalizing the Integrated Development Plan (IDP) for each product, accounting for various development scenarios such as licensing out, mergers and acquisitions (M&A), and specialized regulatory pathways (e.g., Fast Track, Breakthrough Therapy, Conditional Approval). • Leading Investigational New Drug (IND) applications to the FDA and NMPA • Designing a companion diagnostic (CDx) development plan for biomarkers in compliance with FDA regulations and execution • Leading Investigator-Initiated Trials (IITs) to explore the potential of TCE and cellular therapeutic combinations in treating advanced solid tumors • Selecting and managing appropriate Contract Research Organizations (CROs)—global or domestic—and Contract Development and Manufacturing Organizations (CDMOs) • Co-developing the company's business plan to present to various investors • Recruiting and interviewing candidates to strengthen internal capabilities and meet business development needs. Major Achievements • The first BiC product (TCR-TCE to treat advanced solid tumors) has been approved to conduct FIH study in the U.S. and China.

SDM is a full-service clinical research organization (CRO) specializing in supporting biotech and pharmaceutical companies through all phases of drug development with more than 1,300 FTEs, which is founded in 2005 in Beijing. Shanghai Shouyan is a wholly owned subsidiary of SDM Group, which is dedicated to translational medicine and early-stage clinical development of innovative drugs. Key responsibilits include: • Confirm the company strategy (focused service scope) which are including Translational Medicine；Clinical Pharmacology；IIT (Phase 0) Study for Advanced Therapeutics, especially CGT products Early-Stage Clinical Development with adaptive design for innovative therapeutics mainly focusing on drugs in oncology, autoimmune disorders and CNS diseases. • Build and manage a high execution team. The Hardcore Skills of the team: Medical team include medical strategy, medical monitoring and medical writing. Clinical Pharmacology team include clinical pharmacology, quantitative pharmacology and statisticians. Pharmacovigilance team include drug safety physician and project manager. • Company Operation and Financial Goals achievements. Be responsible for the annual financial objectives of the whole company. Serve as primary medical expert for client-facing proposals, bid defenses to shape clinical development strategy, accelerates business growth, and strengthens site and KOL relationships for the organization. Major Achievements • Maintained a Compound Annual Growth Rate (CAGR) of more than 30% for three years. • More than 1000 customers are engaged including Biotech/Biopharma/MNC and evaluated more than 1500 products. Bid success rate is more than 15%. • Interviewed more than 200 candidates with HR support and established a nimble but highly competitive organization. • Stengthen over 100 study Site ward & PI

Genescience Pharmaceutical is a prominent biopharmaceutical company in China, specializing in long-acting growth hormone as its primary product. In 2021, its market capitalization surpassed 200 billion RMB, marking its highest value to date. In 2019 I joined the company working as Chief Medical Officer in Oncology. Key responsibilities include: • Analyze the preclinical research product line to determine the development strategy for each asset and identify potential synergies with existing products in other therapeutic areas (such as combination therapies or the application of the same product for treating both tumors and non-tumor diseases). This will facilitate the creation of a comprehensive product matrix within the company. • Engage in the evaluation of multiple external assets to support licensing agreements or technological collaborations. • Identify the most appropriate Clinical Research Sites and Principal Investigators (PIs) for the specific project and product. Strengthening partnerships through diverse strategies to bolster the company's R&D capabilities and promote long-term sustainability. • Establish and lead the Oncology Clinical Scientific Team from the ground up, encompassing the development and defense of annual budgets (including headcounts), organizational structure, team training and advancement strategies, and regular reporting to the board of directors and executive team. • In relation to clinical operations, pharmacovigilance, data management and statistics, as well as registration, foster close cooperation among various functional departments. Contribute to the development of an agile and efficient innovative drug R&D institute. Major Achievements: The INDs for Anti-CD47 antibody were successful in both China and the United States. The different development strategies are being adopted across the two countries.

Tasly Pharmaceutical Group is a publicly listed company primarily focused on traditional Chinese medicine, while also incorporating chemical generic drugs and biosimilars. Since 2015, the company has been transitioning toward innovative drugs, with the goal of evolving from mere financial investments in such drugs to owning proprietary innovative drug assets. I joined Tasly Group and worked as CMO. Key responsibilities include: • Organizing and prioritizing over 70 products under development across the group, with clinical value as the foremost criterion. Providing expert opinions and strategic recommendations on each product's development pathway, while conducting periodic evaluations to support go/no-go decisions. • Serving as the primary technical evaluator for more than 20 investment decisions at Tasly Capital in both primary and secondary markets. Where required, contributing to on-site due diligence for fewer than 10 projects. • Leading the in-licensing of stem cell-related products from Mesoblast Co., Ltd. • Overseeing the clinical development of anti-EGFR monoclonal antibodies as biosimilars. Major Achievement Successfully in-licensed Mesoblast’s allogeneic mesenchymal precursor cell (MPC) product candidates, including Revascor for the treatment or prevention of chronic heart failure and MPC-25-IC for the treatment or prevention of acute myocardial infarction.

EXUMA Biotech is a clinical-stage biotechnology company dedicated to advancing gene vector delivery solutions and innovative cell and gene therapies, with a focus on improving patient access by overcoming traditional limitations in the field. Founded in 2015, the company leverages over a decade of research in cell and gene therapy to enhance the patient journey, particularly by reprogramming immune cells to target challenging autoimmune diseases and solid tumors in cancer. I joined EXUMA as Chief Medical Officer in 2017. Key responsibilities include: • Oversee the design, conduct, and interpretation of clinical trials of CAR-T therapeutics for solid tumors, ensuring high-quality data collection, monitoring, and reporting • Lead clinical operation team to deliver high-quality trial results on time and within budget • Lead the review and analysis of clinical trial data to drive decision-making and ensure optimal clinical outcomes • Ensure appropriate risk management strategies are in place for the clinical programs, including safety monitoring and adverse event reporting • Collaborate with external stakeholders, including academic institutions, CROs, and KOLs to support the clinical development agenda • Ensure appropriate risk management strategies are in place for the clinical programs, including safety monitoring and adverse event reporting • Be a thought leader in cell and gene therapy, providing clinical insights into scientific developments, competitive landscapes, and emerging technologies Major Achievements: Led a cross-functional team in successfully navigating the ethical review process for the world's first investigator-initiated trial (IIT) clinical study on CAR-T therapy for renal cell carcinoma, completing it in just four months. First, advocate for the combination therapy of CAR-T therapy with antibodies in the treatment of solid tumors, and initiate negotiations for collaboration with companies specializing in antibody development.

The NIBR Shanghai R&D Center is one of Novartis' three major global research and development facilities, alongside those in Boston and Basel. In 2016, I joined the Translational Medicine Asia team at NIBR Shanghai as CSE, where I concentrated on Novartis' early-stage clinical research and development initiatives worldwide. Key responsibilities include:  Responsible for conducting several Phase I-IIb (exploratory) clinical trials focused on autoimmune diseases. • Revised key clinical trial documents for each project to ensure consistency and accuracy across all project materials globally • Supervised functional departments to deliver high-quality outputs on schedule, and provided scientific, medical, and operational expertise to support project success.  Collaborated with the global team to assess preclinical data for various new molecular entities (NMEs) to determine their suitability for advancing into clinical trials and to guide subsequent clinical development strategies. • For those deemed suitable for clinical development, formulated the Global Clinical Development Plan (GCDP). • Assessed the regional medical needs and clinical operational feasibility of global projects to determine Asia-Pacific participation in certain clinical studies. • Estimated the regions, personnel, timelines, and budgets required for the entire clinical trial process. Major Achievements: Develop a comprehensive understanding of the key decision-making criteria and global differentiation strategies for First-in-Class (FIC) products transitioning from the preclinical stage to clinical development.

UT (NASDAQ: UTHR)'s market capitalization is about $20.5–$21 billion in 2026. I joined it in 2012 as CMO (China). My Key Responsibilities include: Clinical Trial Oversight & Medical Monitoring • Oversaw the design, execution, and analysis of the Phase III multinational randomized controlled trial (MRCT) in the Asia-Pacific region which is conducted across 33 countries and regions • Being responsible for the medical monitoring case by case of all centers and subjects in the Asia-Pacific region, and establishing a 24/7 on-call medical monitoring system to ensure the well-being of every participant and the overall quality of the MRCT • Integrate the insights and recommendations from the regulatory, medical, clinical operations, biostatistics, pharmacovigilance, and data management teams to implement reasonable and timely protocol amendments as needed to ensure the efficient conduct and high-quality completion of the trial Clinical & Scientific Strategy as well as Leadership • Lead clinical presentations and represent the company in scientific conferences, advisory boards, and medical meetings in the Asia-Pacific areas • Collaborate with external stakeholders, including academic institutions, CROs, KOLs, and regulators, to support the clinical development agenda • Act as a key clinical resource in interactions with regulatory agencies (NMPA, FDA), ensuring adherence to regulatory requirements in both US and China. Major Achievements: • The MRCT has been praised as "the most successful large-scale phase III international multi-center clinical trial in the cardiovascular field worldwide in the past five years" by WSJ when it completed and reached the primary end points. • The investigational product Orenitram (oral treprostinil for PAH) has been approved to launch to the markets by FDA and EMA.

Johns Hopkins School of Medicine and Johns Hopkins Hospital hold elite global status (#4-7 in key rankings) in neuroscience and related fields, bolstered by groundbreaking research and superior clinical outcomes (excellent survival, reduced long-term symptoms et al). My worked as research associate in JHSM and JHH for 6 years. Key responsibilities include • Conducting pathological investigations into neurodegenerative and neurodevelopmental disorders to identify and validate potential therapeutic targets and associated signaling pathways, which are included but not limited to DISC1 for schizophrenia, LRRK2 for Parkinson’s Disorders (PD), Huntingtin for Huntington’s Disorder (HD), Aβ for Alzheimer’s Disorders (AD), ZPR1 for Spinal Muscular Atrophy(SMA), SOD1 for Amyotrophic Lateral Sclerosis (ALS) et al. • Investigate and elucidate the mechanisms underlying the application of neural stem cells and iPS cell-derived differentiated cells for treating neurodegenerative diseases at molecular, cellular, organoid, and animal model levels. • Worked as sub-Investigator in Phase I ward to conduct Investigator Initiated Trials (IIT) and Company Initiated Trials. Major Achievements • Two papers published in reputable peer-reviewed journals.

Key responsibilities of the postdoctoral research conducted at UMass Medical School include • the role of alterations in the MAP kinase signaling pathway in the pathogenesis and progression of various non-neoplastic conditions, such as MASH, and neoplastic diseases, such as gastric cancer to identify druggable targets and mechanism • Constructing Technetium-99m labeled peptides and anti-sense DNA in the laboratory to form Radionucleotide Drug Conjugate (RDC) for early diagnosis of tumor Major Achievements • Two papers published in reputable peer-reviewed journals.

Working as a clinical physician in Department of Oncological Medicine